**Abstract**

**Background:** The *Rumex acetosa* has been used in medicinal treatment, food technology and phytotherapeutics in Eastern Asia and many other countries. However, its effect on cardiovascular system and antiplatelet activity remained to be known. In this study, we examined the antiplatelet activity of *R. acetosa* in detailed manner to understand underlying mechanism.

**Methods:** To study this, whole blood was obtained from male Sprague Dawley (SD) rats and aggregation of washed platelets measured using light transmission aggregometry. Intracellular calcium ion concentration ([Ca²⁺]i) was measured using Fura-2/AM while ATP release evaluated by luminometer. Activation of integrin αIIbβ₃ analyzed by flow cytometry and clot retraction. Furthermore, we studied the signaling pathways mediated by *R. acetosa* extract by western blot analysis.

**Results:** *R. acetosa* extract markedly inhibited collagen-induced platelet aggregation and ATP release in a dose-dependent manner. It also suppressed [Ca²⁺]i mobilization, integrin αIIbβ₃ activation and clot retraction. The extract significantly attenuated phosphorylation of the MAPK pathway (i.e., ERK1/2, JNK), MKK4, PI3K/Akt, and Src family kinase.

**Conclusion:** Taken together, this data suggests that *R. acetosa* extract exhibits anti-platelet activity via modulating MAPK, PI3K/Akt pathways, and integrin αIIbβ₃-mediated inside-out and outside-in signaling, and it may protect against the development of platelet-related cardiovascular diseases.

**Keywords:** Antiplatelet agent, Integrin αIIbβ₃, MAPK, Platelets, *Rumex acetosa*, Thrombosis

---

**Background**

World Health Organization (WHO) disclosed (EURO/03/06) that cardiovascular disease (CVD) reveal the highest mortality among all diseases in western world. WHO has also stated that CVD accounted for 30% of all the deaths that occurred in 2005. In Europe, CVD remains the primary cause of death accounting for 42% of mortalities in men and 52% of deaths in women [1–3]. Coronary heart disease alone caused almost one in every seven deaths and heart failure caused one in nine deaths in the United States in 2013 [4]. Atherosclerotic plaque disruption and thrombogenic substrate exposure initiate platelet activation and aggregation, triggering coagulation cascade which lead to thrombus formation. Acute myocardial infarction and sudden death are the main clinical manifestations of atherosclerosis [5, 6]. For the last decades, antiplatelet drugs have been developed to prevent cardiovascular disease. However, these drugs have serious side effects; in particular, the side effects of aspirin are gastric ulcers and bleeding, and clopidogrel sometimes results in aplastic anemia and thrombocytopenic purpura [7]. Beside treatment of cardiovascular risk factors and use of antithrombotic agents there is considerable interest in traditional remedies and use of natural food products in prevention of CVD [8–12].

In our effort to discover complementary materials, we found *Rumex acetosa* L, a natural product known to have ethnomedicinal properties. Plants were vital much
before the human civilization. Specially, they have been used to intake as well as traditional medicine to improve health for years. The *Rumex* (dock) species have been used in medical treatment for many centuries owing to their astringent, spasmyloytic, antithrombotic and cholagogic activity [13, 14]. *R. acetosa* is a perennial plant distributed in eastern Asia, Europe, and America [15] and the plant often called ‘Sorrel’, have been used within food technology and as phytotherapeutic materials in Korea and Japan [16]. The phytochemical components of *R. acetosa* extract have recently been identified to be monomeric flavan-3-ols (catechin, epicatechin, and epicatechin-3-O-gallate), A- and B-type procyanidins, and propelargonidins (15 dimers, 7 trimers, 2 tetramers) [17, 18]. This plant’s medicinal properties are related to its tannin content and are useful for the treatment of various ailments [19]. Previous studies reported that *R. acetosa* possessed antioxidant [19, 20], anti-hypertensive [21], antiviral, [22] and anticancer effects [23]. However, information on the antiplatelet effects of *R. acetosa* L extract remained to be discovered. Therefore, we investigated in vitro anti-platelet effect of *R. acetosa* extract and discovered underlying mechanism and signaling pathway in rat platelets (Fig. 1).

**Methods**

**Chemicals and reagents**

Thrombin and Collagen (Native collagen fibrils, type I, from equine tendons) were procured from Chrono-Log Co. (Havertown, PA, USA). ATP assay kit was acquired from Biomedical Research Service Center (Buffalo, NY, USA), while Fibrinogen Alexa Fluor® 488 conjugate was acquired from Molecular Probes (Eugene, OR, USA). Fura-2/AM and dimethyl sulfoxide (DMSO) were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Antibodies against ERK (p44/42), phospho-ERK (p44/42), JNK, phospho-JNK, PI3K (p85/p55), phospho-PI3K (p85/p55), Akt (Ser473), phospho-Akt (Ser473), MKK4, phosphor-MKK4, Src (Tyr416), and phospho-Src (Tyr416) were obtained from Cell signaling (Beverly, MA, USA). Water was acquired from J. T. Baker (Phillipsburg, NJ, USA). All chemicals were of reagent grade.

**Procurement of plant material and extract preparation**

Whole dried plant of *R. acetosa* was collected from Rural Development Administration (RDA) in Suwon city. Dr. Jeong-Hoon Lee and Dr. Seung-Eun Lee at RDA undertook the formal identification of plant materials on the basis of botanical characteristics. A voucher specimen of the plant material has been deposited in National Institute of Horticultural and Herbal Science (NIHHS), Eumseong, Republic of Korea, with Voucher ID (NIHHS 2012–026).

The powder (100 g) of *R. acetosa* plant was extracted with methanol in accelerated solvent extraction system (Dionex, USA) at 50 °C, and evaporated in rotary evaporator (N-1000, Eyela, Japan). Finally, crude extract was obtained and stored at −30 °C for further use in experiments.

**Animals**

Male Sprague Dawley (SD) rats (7 weeks old, ~ 240–250 g) were purchased from Orient Co. (Seoul, Korea). Rats were acclimatized for 1 week before the experiments and accommodated in an animal room with a 12/12-h light/dark cycle at a temperature and humidity of 22 ± 1 °C and 50 ± 10%, respectively. All experiments were carried out in accordance with the National Institutes of Health (NIH) guidelines and protocols approved by the Ethics Committee of the College of Veterinary Medicine, Kyungpook National University (Daegu, Korea); and later, rats were euthanized by an overdose of 5% isoflurane as previously described [24]. Isoflurane exposure was continued after 1 min of breathing stoppage, followed by cervical dislocation for confirmation of euthanasia.

**Platelet preparation**

Preparation of washed platelets was conducted as previously described [25]. Briefly, whole blood was collected from rats via heart puncture and anticoagulated with
ACD solution. Firstly, to obtain PRP, anticoagulated blood was centrifuged at 170×g for 7 min. Remaining RBC’s were removed by centrifuging the PRP at 120×g for 7 min. Subsequently, washed platelets were isolated by centrifuging the PRP at 350×g for 7 min. Platelets were resuspended in Tyrode’s buffer (137 mM NaCl, 12 mM NaHCO₃, 5.5 mM glucose, 2 mM KCl, 1 mM MgCl₂, and 0.3 mM NaHPO₄, pH 7.4) and platelet concentration was adjusted at 3 × 10⁸ cells/mL. All the platelet preparation procedure was performed at room temperature (i.e., 23 ± 2 °C).

**Platelet aggregation assay and scanning electron microscopy analysis**

Platelet aggregation assay was performed as previously described [26]. Aggregation was assessed by light transmission in an aggregometer (Chronolog, Havertown, PA, USA). Briefly, washed platelets were pre-incubated either with vehicle or different concentration of *R. acetosa* extract for 2 min at 37 °C, and then aggregation was induced with collagen for 5 min under continuous stirring condition. The vehicle concentration was held at less than 0.1%.

The scanning electron microscopy (SEM) analysis was performed using a Field Emission Scanning Electron Microscope (SU8220, Hitachi, Japan). After the termination of platelet aggregation, the washed platelets were fixed in 0.5% paraformaldehyde and Osmium tetroxide, dehydrated by ascending concentrations of ethanol, and freeze-dried and analyzed by the SEM.

**[Ca²⁺]ᵢ measurement**

The intracellular calcium mobilization ([Ca²⁺]ᵢ) was assessed with Fura-2/AM [27], and Fura-2 fluorescence in the cytosol was quantified with the spectrofluorometer as previously described by Schaeffer and Blaustein [28] using the following formula: [Ca²⁺]ᵢ = 224 nM × (F − Fmin)/(Fmax − F), where 224 nM is the dissociation constant of the Fura-2-Ca²⁺ complex, and Fmin and Fmax represent the fluorescence intensity levels at very low and high calcium concentration, respectively.

---

**Fig. 2** The inhibitory effect of *R. acetosa* extract on collagen-induced platelet aggregation. Platelets were pre-incubated with or without *R. acetosa* extract (25–200 μg/mL) in the presence of 1 mM CaCl₂ for 2 min at 37 °C with stirring and stimulated with collagen (2.5 μg/mL) for 5 min (a–c). After the aggregation reaction was terminated, platelet aggregation was quantified and expressed as percentage. c Representative scanning electron microscopy images of platelets treated with various concentrations of extract or vehicle (Resting state (a), vehicle (b), *R. acetosa* extract 25 μg/mL (c), 50 μg/mL (d), 100 μg/mL (e), or 200 μg/mL (f)). Each graph shows the mean ± SD of at least four independent experiments. *P < 0.05 and ***P < 0.001 compared to the agonist control.
low and very high Ca\(^{2+}\) concentrations, respectively. Here, \(F_{\text{min}}\) and \(F_{\text{max}}\) is the fluorescence intensity of Fura-2-Ca\(^{2+}\) complex measured at 510 nm when platelet suspension treated with 20 mM Tris/3 mM of EGTA and 1 mM of CaCl\(_2\) solubilized with Triton X-100 (0.1%), respectively; while \(F\) denotes the intensity when suspension is treated with collagen in presence or absence of \(R.\ acetosa\) L extract along 1 mM CaCl\(_2\).

### ATP release assay
Platelets were pre-incubated either with vehicle or different concentration of \(R.\ acetosa\) extract in the presence of 1 mM CaCl\(_2\) at 37 °C for 2 min prior to stimulation with collagen (2.5 μg/mL) for 5 min under continuous stirring condition. Reaction was stopped and suspension was centrifuged at high speed to collect supernatant. ATP concentration was assessed in luminometer (GloMax20/20; Promega, Madison, USA) using an ATP assay kit according to manufacturer’s protocol.

### Measurement of fibrinogen binding to integrin α\(\text{IIb}\)β\(\text{3}\)
Fibrinogen Alexa Fluor® 488 conjugate binding to integrin α\(\text{IIb}\)β\(\text{3}\) on platelets was assessed by flow cytometry as previously described [29]. Briefly, washed platelets were pre-incubated either with vehicle or different concentrations of \(R.\ acetosa\) extract along with 0.2 mM CaCl\(_2\) for 2 min. The platelets were stimulated with collagen for 5 min, following incubation with fibrinogen Alexa Fluor® 488 (20 μg/mL) for 5 min at room temperature, and then fixed with 0.5% paraformaldehyde for 30 min at 4°C. Alexa Fluor 488-fibrinogen binding to integrin α\(\text{IIb}\)β\(\text{3}\) on platelets was quantified by flow cytometry using FACSAria™ III flow cytometer® (BD Biosciences, San Jose, CA, USA) while data were analyzed using CellQuest software (BD Immunocytometry Systems, San Jose, CA, USA).

### Clot retraction
The in vitro effect of \(R.\ acetosa\) on outside-in signaling through integrin activation was assessed by measuring clot retraction as previously described [29]. PRP (250 μL) was incubated with vehicle, \(R.\ acetosa\) extract or Y-27632 (Rock inhibitor) for 2 min, following addition of RBC’s (5 μL) and Tyrode’s buffer to raise the volume up to 1 mL. Clot retraction was initiated by addition of thrombin (1 U/mL) and observed for 90 min at room temperature. Finally, clot weight was measured to assess clot retraction.

### Immunoblotting
Platelets were pre-incubated either with vehicle or different concentration of \(R.\ acetosa\) extract in the presence of 1 mM CaCl\(_2\) at 37 °C for 2 min prior to stimulation with collagen (2.5 μg/mL) for 5 min under continuous stirring condition. Reacting was terminated by adding lysis buffer [0.125 M Tris–HCl, pH 6.8; 2% SDS, 2% β-mercaptoethanol, 20% glycerol, 0.02% bromophenol blue, 1 μg/mL phenyl methyl sulfonyl fluoride (PMSF), 2 μg/mL aprotinin, 1 μg/mL leupeptin, and 1 μg/mL pepstatin A]. Proteins were quantified by BCA assay (PRO-MEASURE; iNtRON Biotechnology, Seoul, Korea) and total cell proteins (35 μg) from the lysates were segregated on 10% SDS-PAGE followed by transferring to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked in 5% skim milk and then probed with primary and secondary antibodies accordingly in 5% BSA solution. Finally, antibody binding was pictured.

---

**Fig. 3** The inhibitory effect of \(R.\ acetosa\) extract on [Ca\(^{2+}\)]\(_i\) elevation and granule secretion. a Washed platelets were incubated with a calcium fluorophore (5 μM, Fura-2/AM), following treatment with different concentrations of \(R.\ acetosa\) extract and stimulated with collagen. b Platelets were pre-incubated with or without \(R.\ acetosa\) extract (25–200 μg/mL) in the presence of 1 mM CaCl\(_2\) for 2 min at 37°C with stirring and stimulated with collagen for 5 min. Reaction was stopped and ATP release assay was carried out. The results are presented as the mean ± SD of at least four independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control.
by enhanced chemiluminescence (iNtRON Biotechnology, Seoul, Korea).

**Statistical analysis**
To assess statistical significance among observed differences, the obtained data were analyzed by one-way analysis of variance (ANOVA) followed by post-hoc Dunnett’s test (SAS Institute Inc., Cary, NC, USA). The given data are presented as the mean ± standard deviation (SD). P-values of 0.05 or less were considered statistically significant.

**Results**

**Effect of *R. acetosa* extract on collagen-induced platelet aggregation**
Our result showed that *R. acetosa* extract strongly inhibited platelet aggregation induced by collagen in dose dependent manner (Fig. 2a-b). Platelet activation causes granule secretion, shape change and fibrin formation ultimately leading to platelet aggregation. We confirmed the effect of *R. acetosa* L extract on collagen-induced platelet shape change from inactivated to activated state of platelets under electron microscopy (Fig. 3).

**Fig. 4** The inhibitory effect of *R. acetosa* extract on inside-out and outside-in signaling. Platelets were pre-incubated with or without *R. acetosa* extract (25–200 μg/mL) in the presence of 0.2 mM CaCl₂ for 2 min at 37 °C with stirring and stimulated with collagen for 15 min at 37 °C. (A) Representative FACS analysis results of five independent trials [Resting (a), Vehicle (b), *R. acetosa* extract 25 μg/mL (c), 50 μg/mL (d), 100 μg/mL (e), 200 μg/mL (f), and, EGTA 10 μM (g)]. (B) Bar graph summarizing the inhibitory effect of *R. acetosa* extract on fibrinogen binding. (C) Thrombin (1 U/mL) was used to initiate clot retraction in presence or absence of *R. acetosa* (50–200 μg/mL) or Y-27632 (10 μM). Clot retraction was observed for 90 min and representative images of clot retraction at 1 h (c), while bar graph (d) showing inhibitory effects of *R. acetosa* extract on clot retraction. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control.
microscope and found dose dependent inhibition of platelet activation and shape change compared with vehicle treated platelets (Fig. 2c).

**R. acetosa** extract markedly reduced [Ca\(^{2+}\)] mobilization and granule secretion

We found that pretreatment of platelets with **R. acetosa** extract markedly reduced the elevation in [Ca\(^{2+}\)] in collagen stimulated platelets in a dose-dependent manner (Fig. 3a).

Also, collagen strongly increased ATP release from dense granules in vehicle treated platelets by 3-fold in comparison with resting platelets. Our results show that platelets pretreated with **R. acetosa** extract significantly abridged ATP release in a dose-dependent manner (Fig. 3b).

**Inhibitory effect of R. acetosa** extract on inside-out and outside-in signaling

We found that **R. acetosa** extract reduced affinity of fibrinogen binding to integrin \(\alpha_{IIb}\beta_3\) (Fig. 4a-b) and clot retraction via Rho kinase inhibition in a dose-dependent manner (Fig. 4c-d).

**Effect of R. acetosa** extract on MAPK, PI3K/Akt and Src phosphorylation

To explore the underlying mechanism, we further studied the phosphorylation of downstream signaling proteins including MAPK’s and MKK4. Our result shown that **R. acetosa** extract reduced the phosphorylation of ERK1/2 and JNK. **R. acetosa** extract also inhibited the phosphorylation of MKK4 which is an upstream signaling molecule of JNK (Fig. 5a).

Our result also revealed that **R. acetosa** extract markedly inhibited collagen-induced PI3K/Akt signaling in a dose-dependent manner. In addition, phosphorylation of Src family kinases plays a role in GPVI-mediated platelet activation and we found that **R. acetosa** extract significantly reduced the activation of Src family kinase (Fig. 5b).

**Discussion**

Cardiovascular diseases such as atherosclerosis, thrombosis, and myocardial infarction are the major causes of mortality in the modern world. Platelets play critical roles in hemostasis, thrombosis,
immunity, and inflammation. At the site of vascular injury, platelets are activated by agonists such as collagen, adenosine diphosphate (ADP), and thrombin. These agonists initiate signal transduction through their specific receptors leading to platelet morphology changes, granule secretion, and aggregation [30]. However, aberrant or over-activation of platelet formation induces a platelet plug and thrombus formation, which can lead to serious ailments such as atherosclerosis. Therefore, the development of antiplatelet agents is a basic goal in cardiovascular research [31].

In the present study, we explored whether *R. acetosa* extract inhibits collagen-stimulated platelet activation and our results showed that *R. acetosa* extract markedly inhibited collagen-stimulated platelet aggregation in a dose-dependent manner. To demonstrate the inhibitory mechanism of *R. acetosa* extract, we further examined downstream signaling components such as intracellular calcium mobilization, granule secretion, integrin signaling, and various proteins phosphorylation. Cytosolic calcium level is known to play a critical role in platelet activation. Increasing calcium levels activates several signaling pathways involved in actin-myosin interaction, protein kinase c (PKC), calmodulin, and calcium-dependent proteases [32]. Our results show that *R. acetosa* extract strongly inhibited the intracellular mobilization of calcium. Intracellular Ca\(^{2+}\) mobilization is also essential for \(\alpha\)- and \(\delta\)-granule secretion [33]. Granule secretion improves platelet activation and recruitment of circulating platelets into injured blood vessels. It is also important for thrombus formation. In this study, we found that treatment with *R. acetosa* extract decreased ATP release from dense granules in collagen-stimulated platelets. Platelets express integrins such as \(\alpha_{IIb}\beta_3\) (fibrinogen receptor), \(\alpha_\beta_1\) (collagen receptor), and \(\alpha_\beta_1\) (fibronectin receptor). These integrin’s regulate signal transduction by various mechanisms. When a specific ligand binds to integrin \(\alpha_{IIb}\beta_3\), the fibrinogen receptor changes its conformational structure which enhances affinity to bind with fibrinogen following platelet adhesion and clot retraction [34]. Our data suggests that pretreatment with *R. acetosa* extract dose-dependently blocked fibrinogen binding to integrin \(\alpha_{IIb}\beta_3\) and clot retraction.

Mitogen-activated protein kinases (MAPKs), including ERK1/2 and JNK1, exist in platelets and mediate proliferation, migration, and apoptosis. MAPKs are phosphorylated by several agonists, such as collagen, ADP, and thrombin, and are important for “outside-in” as well as “inside-out signaling” [35]. The PI3K/Akt signaling pathway also is critical for platelet activation and aggregation. Further, PI3Ks are necessary for the tyrosine phosphorylation-based signaling pathways initiated by GPVI or \(\alpha_{IIb}\beta_3\) [36]. The results of our study showed that *R. acetosa* extract inhibited phosphorylation of ERK1/2, JNK, and MKK4. Moreover, the PI3K-Akt pathway was also blocked by *R. acetosa* extract. Specific ligand binding to GPVI, the immunoreceptor tyrosine-based activation motif (ITAM) within the FcRy cytoplasmic domain, is a tyrosine moiety phosphorylated by Src family kinases (including Fyn and Lyn). Phosphorylation of Src family kinases is important for GPVI-mediated platelet activation [36]. Our data showed that SFK phosphorylation induced by collagen was significantly decreased by treatment with *R. acetosa* extract. Figure 6 showing a graphical summary of effects of *R. acetosa* extract on platelet intracellular signaling.

Previous reports have suggested that methanolic extract of *R. acetosa* contained several pharmacological compounds such as catechin, epicatechin and epigallocatechin-3-O-gallate [19, 37], while these compounds have been known for their antiplatelet activities [38]. Therefore, antiplatelet effects observed in present study could be attributed to catechin and epicatechin contained in *R. acetosa* extract. We acknowledge that there are some limitations i.e., study could explore in vitro antiplatelet properties of extract in collagen-stimulated rat platelets. Future studies may be planned to discover in vivo antiplatelet aspects and unravel other pathways involved in its antithrombotic mechanism.

![Fig. 6 Summary of effects of *R. acetosa* extract on platelet intracellular signaling](image)
Conclusion

We conclude that *R. acetosa* extract has potent anti-platelet effects and good candidate in the new era of ethnomedicine against cardiovascular diseases, including atherosclerosis, ischemic stroke, and myocardial infarction. Future studies could explore further in vivo effects of the extract and validate its pharmacological compounds in animals and humans as potential antithrombotic agents.

Abbreviations

ADP: Adenosine diphosphate; Akt: Protein kinase B; DMSO: Dimethyl sulfoxide; ERK: Extracellular signal-regulated kinase; GPVI: Glycoprotein VI; JNK: c-Jun N-terminal kinase; MAPK: Mitogen-activated protein kinase; MKK4: Mitogen-activated kinase kinase 4; PI3K: Phosphatidylinositol 3-kinases; PRP: Platelet-rich plasma; SFK: Src family kinase

Acknowledgments

The present data is a part of Master’s dissertation of Dahye Jeong.

Authors’ contribution

MHR and DJ designed and conceptualized the study. DJ and MI performed experiments and wrote the manuscript. MHR critically revised the manuscript. DHL, SBH, JWO, and MHR technically assisted in the experiments and preparation of the manuscript. MHR supervised the whole research work. All authors read and approved the final manuscript.

Funding

This research was supported and funded by the National Research Foundation of Korea (2018R1D1A1A09083797). Funding body did not participate in the design of the study, collection, analysis, interpretation of data or in writing the manuscript.

Availability of data and materials

The dataset generated during the present study is available upon reasonable request to the author (Prof. Man Hee Rhee).

Ethics approval

All experiments were carried out in accordance with the National Institutes of Health (NIH) guidelines and approved by the Ethics Committee of the College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea (Permit number: 2017-0014).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Laboratory of Veterinary Physiology and Cell Signalling, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Republic of Korea.

2Department of Biomedical Laboratory Science; and Molecular Diagnostics Research Institute, Nameeaeoung University, Cheonan 31020, Republic of Korea.

3Department of Clinical Laboratory Science, Chungbuk Health & Science University, Cheongju-si, Chungbuk 28150, Republic of Korea.

4Department of Animal Biotechnology, Konkuk University, Seoul 05029, South Korea.

Received: 5 November 2019 Accepted: 11 March 2020

Published online: 23 March 2020

References

1. Gielen S, Landmesser U. The year in cardiology 2013: cardiovascular disease prevention. Eur Heart J. 2014;35(5):307–12.

2. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2013;34(39):3028–34.

3. Shafiq G, Tatinati S, Ang WT, Veluvelu KC. Automatic identification of systolic time intervals in seismocardiogram. Sci Rep. 2016;6:37524.

4. Mozaffarian D, Benjamin EL, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, et al. Heart disease and stroke Statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e85–360.

5. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. Atherosclerosis and high-risk plaque: part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol. 2005;46(7):1209–18.

6. Shin J-H, Kwon H-W, Rhee MH, Park H-J. Inhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release. J Ginseng Res. 2019;43(2):236–41.

7. Barnett NE, Holbrook L, Jones S, Kaiser WI, Moraes LA, Rana R, Sage T, Stanley RG, Tucker KL, Wright B, et al. Future innovations in anti-platelet therapies. Br J Pharmacol. 2008;154(5):918–39.

8. Rastogi S, Pandey MW, Rawat A. Traditional herbs: a remedy for cardiovascular disorders. Phytomedicine. 2016;23(11):1082–9.

9. Irfan M, Kim M, Rhee MH. Anti-platelet role of Korean ginseng and ginsenosides in cardiovascular diseases. J Ginseng Res. 2020;44(1):24–32.

10. Krasinska B, Osińska A, Osińska M, Krasinka A, Rzymiński P, Tykarski A, Krasinski Z. Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk—a randomised, controlled trial. Arch Med Sci. 2018;14(4):773.

11. Poniedziak Z, Siwulska M, Water A, Komaniecka I, Komosa A, Gacecka M, Magdzik Z, Mleczek M, Niedzielski P, Proch J. The effect of mushroom extracts on human platelet and blood coagulation: in vitro screening of eight edible species. Nutrients. 2019;11(12):3040.

12. Kim J-H. Pharmacological and medical applications of Panax ginseng and ginsenosides: a review for use in cardiovascular diseases. J Ginseng Res. 2018;42(3):264–9.

13. Wegiera M, Smolzarz HD, Bogucka-Koda A. Rumex L. species induce apoptosis in 1301, EOL-1 and H-9 cell lines. Acta Pol Pharm. 2013;69(3):487–9.

14. Jeon B-R, Irfan M, Lee SE, Lee JH, Rhee MH. Astilbe chinensis modulates platelet aggregation and adhesion. J Food Drug Anal. 2018;26:119–26.

15. Kato T, Morita Y. C-glycosylflavones with acetyl substitution from Rumex acetosa L. Chem Pharm Bull. 2005;28(11):2158–62.

16. Bae J-Y, Lee YS, Han SY, Jeong EJ, Lee MK, Koo B-S, Ryu S-Y, Han Y-H, Lee S-I, Lee D-U. Antiproliferative and cytotoxic effects of endemic plants extracts in Korea. Korean J Med Crop Sci. 2006;18(4):49.

17. Lee N-J, Choi J-H, Koo B-S, Ryu S-Y, Han Y-H, Lee S-I, Lee D-U. Inhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release. J Ginseng Res. 2019;43(2):236–41.

18. Gescher K, Hensel A, Hafezi W, Derksen A, Kuhn J. Oligomeric procyanidins from Rumex acetosa increase monocyte production of superoxide anion and cytochrome c in vitro. FEBS Lett. 2005;46(7):1209–18.

19. Lee N-J, Kwon H-W, Rhee MH, Park H-J. Inhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release. J Ginseng Res. 2019;43(2):236–41.
27. Jeong D, Irfan M, Kim S-D, Kim S, Oh J-H, Park C-K, Kim H-K, Rhee MH. Ginsenoside Rg3-enriched red ginseng extract inhibits platelet activation and in vivo thrombus formation. J Ginseng Res. 2017;41(4):548–55.
28. Schaeffer J, Blaustein MP. Platelet free calcium concentrations measured with fura-2 are influenced by the transmembrane sodium gradient. Cell Calcium. 1989;10(2):101–13.
29. Irfan M, Jeong D, Saba E, Kwon H-W, Shin J-H, Jeon B-R, Kim S, Kim S-D, Lee D-H, Nah S-Y. Gintonin modulates platelet function and inhibits thrombus formation via impaired glycoprotein VI signaling. Platelets. 2019;30(5):589–98.
30. Tsuji M, Ezumi Y, Arii M, Takayama H. A novel association of fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem. 1997;272(38):23528–31.
31. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010;9(2):154–69.
32. Li Z, Delaney MK, O’Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol. 2010;30(12):2341–9.
33. Lopez E, Bermejo N, Berna-Erro A, Alonso N, Salido G, Redondo P, Rosado J. Relationship between calcium mobilization and platelet α-and δ-granule secretion. A role for TRPC6 in thrombin-evoked δ-granule exocytosis. Arch Biochem Biophys. 2015;585:75–81.
34. Calderwood DA. Integrin activation. J Cell Sci. 2004;117(Pt 5):657–66.
35. Adam F, Kauskot A, Nurden P, Sulpi ce E, Hoya larts MF, Davis RJ, Rosa JP, Bro ycaert M. Platelet JNK1 is involved in secretion and thrombus formation. Blood. 2010;115(20):4083–92.
36. Senis YA, Mazharian A, Mori J. Src family kinases: at the forefront of platelet activation. Blood. 2014;124(13):2013–24.
37. Stöggl WM, Huck CW, Bonn GK. Structural elucidation of catechin and epicatechin in sorrel leaf extracts using liquid-chromatography coupled to diode array-, fluorescence-, and mass spectrometric detection. J Sep Sci. 2003;27(7–8):524–8.
38. Santhakumar AB, Bulmer AC, Singh I. A review of the mechanisms and effectiveness of dietary polyphenols in reducing oxidative stress and thrombotic risk. J Hum Nutr Diet. 2014;27(1):1–21.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.